Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Dbv Technologies ADR (NQ: DBVT )

0.6995 +0.0095 (+1.38%)
Streaming Delayed Price Updated: 1:49 PM EDT, Apr 16, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 13,272
Open 0.6900
Bid (Size) 0.6900 (18)
Ask (Size) 0.6999 (1)
Prev. Close 0.6900
Today's Range 0.6900 - 0.6999
52wk Range 0.6500 - 2.370
Shares Outstanding 55,096,537
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Information regarding the total number of voting rights and total number of shares of the Company as of March 31, 2024
From DBV Technologies S.A.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga

Performance

YTD
-26.16%
-26.16%
1 Month
-9.16%
-9.16%
3 Month
-19.73%
-19.73%
6 Month
-39.70%
-39.70%
1 Year
-56.01%
-56.01%

More News

Read More
DBV Technologies announces filing of 2023 Annual Report on Form 10-K and Universal Registration Document
From DBV Technologies S.A.
Via GlobeNewswire
DBVT Stock Earnings: DBV Technologies Beats EPS, Beats Revenue for Q4 2023
Via InvestorPlace
A Preview Of DBV Technologies's Earnings
Via Benzinga
DBV Technologies Reports Full Year 2023 Financial Results and Business Update
From DBV Technologies S.A.
Via GlobeNewswire
DBV Technologies to Report Full Year 2023 Financial Results and Business Update on March 7, 2024
From DBV Technologies S.A.
Via GlobeNewswire
DBV Technologies to Participate in Upcoming AAAAI 2024 Congress
From DBV Technologies S.A.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Earnings Scheduled For March 7, 2024
Via Benzinga
DBV Technologies And 2 Other Stocks Under $2 Insiders Are Buying
Via Benzinga
Topics Stocks
Exposures US Equities
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
From DBV Technologies S.A.
Via GlobeNewswire
Information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2023
From DBV Technologies S.A.
Via GlobeNewswire
Top 5 Health Care Stocks That Could Blast Off In December
Via Benzinga
DBV Technologies Announces 2-Year Results from Ongoing Phase 3 Open-Label Extension to the EPITOPE Trial (EPOPEX) of Viaskin™ Peanut in Toddlers
From DBV Technologies S.A.
Via GlobeNewswire
Monthly information regarding the total number of voting rights and total number of shares of the Company as of October 31, 2023
From DBV Technologies S.A.
Via GlobeNewswire
DBV Technologies to Present New Data at ACAAI 2023
From DBV Technologies S.A.
Via GlobeNewswire
Why Plus Therapeutics Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket
Via Benzinga
DBV Technologies Receives Requested Feedback from FDA on Protocol Design Elements for COMFORT Safety Studies and Reports Third Quarter 2023 Financial Results
From DBV Technologies S.A.
Via GlobeNewswire
DBV Technologies to Report Third Quarter 2023 Financial Results and Business Update
From DBV Technologies S.A.
Via GlobeNewswire
DBV Technologies Announces Appointment of Virginie Boucinha as Chief Financial Officer
From DBV Technologies S.A.
Via GlobeNewswire
Monthly information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2023
From DBV Technologies S.A.
Via GlobeNewswire
DBV Technologies to Participate in Upcoming Investor Conference
From DBV Technologies S.A.
Via GlobeNewswire
Stereotaxis And 3 Other Stocks Under $2 Insiders Are Aggressively Buying
Via Benzinga
Topics Stocks
Exposures US Equities
DBV Technologies And 3 Other Penny Stocks Insiders Are Buying
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.